ライフサイエンスコーパス: tolerogen

1 anti-CD40L monoclonal antibody were used as tolerogen.

2 T cells from strong stimulation by exogenous tolerogen.

3 ry CD8 T cells in mice to these two forms of tolerogen.

4 tructure, location, and concentration of the tolerogen.

5 e potency and density of MHC class I-peptide tolerogen.

6 sing novel TCRs that no longer recognize the tolerogen.

7 alternate TCR that no longer recognizes the tolerogen.

8 ry and is driven by a peripherally expressed tolerogen.

9 target epitopes are not available as B cell tolerogens.

10 re still susceptible to autoantigen-specific tolerogens.

11 distinct from naked peptide or protein-based tolerogens.

12 nduction of apoptosis in TNP-spl, making the tolerogen 100 times more potent.

13 de in IFA was administered parenterally as a tolerogen, after the development of a primary T cell imm

14 Ig-myelin oligodendrocyte glycoprotein (MOG) tolerogen, an Ig carrying the MOG35-55 peptide.

15 ble to tolerance induction, both the form of tolerogen and location of the T cells can determine thei

16 vation and memory markers are induced by the tolerogen and may exert their influence via cytokines to

17 e fact that they are both driven by the same tolerogen and restricted to mature CD4(+) T cells.

18 T cells can determine their accessibility to tolerogen and the degree to which they are successfully

19 lin basic protein are nevertheless effective tolerogens and are able to anergize autoreactive T cells

20 lagellin challenge antigen and a murine IgG1 tolerogen, both expressing the lambda repressor epitope

21 m for studying the feasibility of engineered tolerogens, consisting of a recombinant flagellin challe

22 Short peptide-based tolerogens, devoid of immunogenic and pathogenic potenti

23 A phase I trial of a tolerogen directed at anti-beta2-glycoprotein I antibodi

24 The first tolerogen, directed at anti-dsDNA responses in SLE, did

25 cell death of DC and that IL-12 converts the tolerogen DNTB into an immunogen by preventing DNTB-indu

26 to DNFB, showing that IL-12 can convert the tolerogen DNTB into an immunogen.

27 Thus, tolerogen-driven receptor revision in peripheral T cells

28 t Th2 cells displayed reduced motility after tolerogen exposure similar to Th1 cells after immunizati

29 by altering the affinity of the peptide-MHC tolerogen for TCR, we have confirmed that this mechanism

30 Donor-derived sMHC are potential tolerogens for down-regulating the cytotoxic T-cell resp

31 that such vaccines may serve as Ag-specific tolerogens for the treatment of autoimmune disease.

32 Two B cell tolerogens have been used in human trials.

33 peptide, however, by 48 h after exposure to tolerogen, IL-2 production dropped and was replaced by h

34 Selected analogue peptides were tested as tolerogens in neonatal mice.

35 imaging, and T cell behavior was analyzed on tolerogen-induced modulation.

36 eatment on T cells in vivo demonstrated that tolerogen injection resulted in rapid T cell activation

37 ely, the data suggest that multiple receptor-tolerogen interactions regulate autoreactive cells in th

38 In TCRbeta chain transgenic mice, tolerogen-mediated chronic peripheral selection against

39 We propose that the primary tolerogen of dual reactive B cells in this model is not

40 l is not ssDNA, but a strongly cross-linking tolerogen, presumably basement membrane laminin, that tr

41 s strongly suggest that TCR revision rescues tolerogen-reactive peripheral T cells from deletion.

42 responding in vivo, Ndfip1 was necessary for tolerogen-reactive T cells to exit cell cycle after one

43 ymphoid organs rapidly up-regulate PD-1 upon tolerogen recognition.

44 RF B cells exposed to tolerogen remain competent to secrete RF in vitro if pro

45 upon lymphorepletion even in the absence of tolerogen (self-antigen), challenging the prevailing par

46 33D1 was 100- to 1000-fold more potent as a tolerogen than an isotype-matched control rat IgG2b mAb.

47 as a unique class of inflammation-dependent tolerogens that are mechanistically distinct from naked

48 Cells are driven by the tolerogen to enter one of two tolerance pathways, deleti

49 otic death might provide a primary source of tolerogen to shape the immune repertoire, or be the targ

50 issue-derived CII when given as i.v. or oral tolerogens to suppress arthritis.

51 graft reactive CD4(+) T cells transferred to tolerogen-treated recipients at the time of transplantat

52 termed OVA-psigma1, was developed to enhance tolerogen uptake.

53 vious studies using adult splenocytes as the tolerogen, we achieved a higher frequency of tolerance w

54 nitrophenyl-coupled splenocytes (TNP-spl) as tolerogen, we found that Fas signaling for apoptosis in

55 A panel of analogues of the tolerogen were tested for their capacity to terminate th

56 ts such as anti-BlyS, anti-CD154, and B cell tolerogens will also be covered.

57 ior to inflammation and can be expanded with tolerogen without further differentiation.